1 / 18

From Venom to Synthetic Inhibitor a Closer L ook A t Captopril

From Venom to Synthetic Inhibitor a Closer L ook A t Captopril . http://www.latoxan.com/VENOM/SNAKE/Bothrops-jararaca.php. Advanced Organic Chemistry Dr. Clower By: Sam Kennedy. http://www.latoxan.com/VENOM/SNAKE/Bothrops-jararaca.php. Overview. Ace Inhibitors

cybil
Download Presentation

From Venom to Synthetic Inhibitor a Closer L ook A t Captopril

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. From Venom to Synthetic Inhibitor a Closer Look At Captopril http://www.latoxan.com/VENOM/SNAKE/Bothrops-jararaca.php Advanced Organic Chemistry Dr. Clower By: Sam Kennedy http://www.latoxan.com/VENOM/SNAKE/Bothrops-jararaca.php

  2. Overview • Ace Inhibitors • Renin Angiotensin Aldosterone System • Ace Mechanism & Binding Interaction • Development of Captopril • Captopril Binding/Optimization • Final FDA Approval of Captopril • Captopril Synthesis

  3. ACE Inhibitors • Angiotensin converting enzyme (ACE) catalises the conversion of angiotensin I (A-I) to angiotensin II(A-II) • The ACE activity directly related to hypertension • AngII is the blood pressure regulating hormone • ACE inhibitors are a major class of antihypertensive drugs • Captopril, was the first orally active ACE inhibitory antihypertensive

  4. Renin Angiotensin Aldosterone System http://en.wikipedia.org/wiki/Renin%E2%80%93angiotensin_system

  5. ACE Mechanism Of Action www.york.ac.uk/res/pac/teaching/AsymmSynth%20handouts.pdf

  6. ACE Mechanism & Binding Interactions http://www.4college.co.uk/a/Md/medicine.php

  7. Development of Captopril • How did they design the drug? • From studies of the snake venom, the researchers found that one particular variation of bradykinin, a nine-amino-acid peptide called teprotide • it effectively reduced blood pressure and seemed to have a long-lasting effect. However, it was expensive, and could not be administered orally. • Miguel Ondetti, Bernard Rubin and David Cushman at the at the U.S. drug company Squibb (now Bristol-Myer Squibb) systematically modifying the structure of tetroprideto see what effect it had on blood pressure. • It turned out that the active part was the proline group at the end teprotide • The rest of the molecule helped bind this to the active site in the ACE enzyme.

  8. Development of Captopril Cont. Teprotide Lead http://en.wikipedia.org/w/index.php?title=File:Teprotide.svg&page=1

  9. Development of Captopril Cont. L-Proline marvindraw

  10. Development of Captopril Cont.Succinyl-L-proline

  11. Development of Captopril Cont. Captopril

  12. Final FDA Approval of Captopril • Captopril gained FDA approval on April 6, 1981, • adverse side-effects, cough, rashes, and taste disturbances • Other ACE-inhibitor drugs have been developed based on Captopril's structure

  13. Captopril Binding Interaction/Optimization http://www.4college.co.uk/a/Md/medicine.php

  14. Captopril Through the Baylis-Hillman Reaction Reaction Scheme Reagents and Conditions. a: acryloyl chloride,KOH, H2O-Acetone, 0°,70%; b: aq. CH2O 40%, H 2O, ultrasound, 47%;c: H2, Pd/C, 92% (4:1 diastereomericratio); d: silica gel, 70% of the major isomer; e: SOCl2, THF-H 2O; thenNH4SH/H 2O, 87%. Almeida et al.

  15. Future Directions • Chronic dehydration • Lactotripeptides Val-Pro-Pro and Ile-Pro-Pro produced by the probiotic ''Lactobacillus helveticus'' ACE-inhibiting and antihypertensive functions. • Metabolic pathway of production of ACE

  16. References • 1.Almeida Wanda P. & Feltrin Melissa P. (2006). A Synthesis of Captopril Through a Baylis-Hillman Reaction. Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry. 33 (7), 1141-1146. • 2.Atlas Steven A. (2007). The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacological Inhibition. Supplement to Journal of Managed Care Pharmacy. 13 (S-b), S9-S20. • 3.Bhaskar J. Bhuyan & GovindasamyMugesh. (2011). Angiotensin converting enzyme inhibitors in the treatment of hypertension. Current Science. 101 (7), 881-887. • 4. Cushman David w. & Ondetti miguel A. (1999). Design of angiotensin converting enzyme inhibitors. Nature. 5 (10), 1110-1112. • 5.Cushman David w. & Ondettimiguel A. (1991). History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. American Heart Association 1991;17:589-92, doi:10.1161/01.HYP.17.4.589 • 6.Mohd Akit et al.. (2011). Structural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captopril. The FEBS Journal. 278 (1), 3644-3650.

  17. Acknowledgements • Dr. Joshua Parker‎ • Dr. Caroline Clower • Clayton State Biology/ Chemistry Department

More Related